Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
Wealth management: 4 rising suns in financial services space

2018-07-11 moneycontrol
The 2 decade old Indian wealth management industry seems to be coming of age. In line with global trends, wealth management and private banking is fast emerging as an attractive business model for many financial institutions in India.
EDELWEISS KMBKY MS.PRE MS.PRF MOTILALOFS MS.PRG IIFL 532922 532636 MS.PRA 532892 MS.PRI MS.PRK KOTAKBANK 500247 MS

0
IIFL Holdings Limited - AGM/Book Closure

2018-07-09 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IIFL 532636

0
IIFL Finance raises Rs 325 crore via masala bonds from UK#39;s CDC Group

2018-07-05 moneycontrol
IIFL Holdings subsidiary IIFL Finance has got Rs 325 crore funding from UK government's development finance institution CDC Group Plc by way of masala bonds. CDC has a minority stake in IIFL Finance (India Infoline Finance Ltd).
IIFL 532636

0
IIFL Holdings Limited - Press Release

2018-07-05 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IIFL 532636

6
National Stock Exchange of India (NSE) Signs Post-Trade Technology and Strategic Partnership Agreement with Nasdaq

2018-07-02 globenewswire
MUMBAI, India and STOCKHOLM, Sweden, July 02, 2018 (GLOBE NEWSWIRE) -- The National Stock Exchange of India (NSE) and Nasdaq have officially signed an agreement for Nasdaq to deliver a customized real-time clearing, risk management and settlement technology to one of the world’s largest stock exchanges. In addition to the post-trade agreement, Nasdaq has also signed an agreement with NSEIT to utilize NSEIT’s capability in implementations and project augmentation globally.
IDFCBANK HDB 500180 HDFCBANK IIFL 532636 539437

0
Varroc IPO subscribed over 3.5 times on last day of issue

2018-06-28 livemint
Mumbai: Auto components maker Varroc Engineering Ltd’s ₹ 1,955 crore initial public offering (IPO) was subscribed 3.59 times on Thursday, the final day of the share sale, according to data from the stock exchanges. As of 7pm, the portion of shares reserved for institutional investors in the Varroc Engineering IPO was subscribed 9.16 times, while those reserved for retail investors and high net-worth individuals (HNIs) were subscribed 94% and 2.
IIFL 532636

10
HDFC Mutual Fund gets Sebi nod for IPO

2018-06-28 livemint
New Delhi: HDFC Asset Management Co. Ltd, the country’s largest mutual fund, on Thursday received Securities and Exchange Board of India’s (Sebi) approval to float an initial public offer (IPO).
523405 SLFPF SL IIFL HDFC 532636 539516 HDFCNIFETF HDB 500180 HDFCBANK 500010 HDFC JMFINANCIL SLFPY

0
Lakshmi Vilas Bank board approves up to 15 cr equity share issue, Rs 250 cr fund raise via bonds

2018-06-26 moneycontrol
Lakshmi Vilas Bank (LVB) today said its board has approved an issue of up to 15 crore equity shares or convertible securities to raise funds, estimated to be around Rs 1,695 crore. The board also approved a proposal to raise up to Rs 250 crore through issue of bonds, debentures or securities on private placement basis.
LAKSHVILAS 534690 IIFL 532636

1
Varroc Engineering IPO receives over 30% subscription on Day 1

2018-06-26 livemint
Mumbai: The Varroc Engineering IPO was subscribed 33% on Tuesday, the first day of the initial public offering. As of 5 pm of Tuesday, the portion of shares reserved for institutional investors was subscribed 104%, while those reserved for retail investors and high net-worth individuals (HNIs) were subscribed 10% and 1%, respectively. The auto components firm, backed by Tata Opportunities Fund, has fixed a price band of ₹ 965-967 per share.
MOZTY VC MOTHERSUMI IIFL 532636 517334

0
Varroc Engineering IPO subscribed 0.06 times; Rs 584 cr raised from anchor investors

2018-06-26 thehindubusinessline
Varroc Engineering’s initial share sale was subscribed 0.06 times with 8,78,880 shares bid against 1,41,85,212 on offer, according to NSE data as of 2 pm local time.
IIFL 532636

1
IIFL Holdings appoints Sumit Bali as CEO, ED of India lnfoline

2018-06-25 moneycontrol
Financial services firm IIFL Holdings today announced appointment of Sumit Bali as CEO and Executive Director (ED) of its subsidiary India lnfoline Finance with effect from today.
KMBKY KOTAKBANK IIFL 500247 532636

0
IIFL Holdings Limited - Updates

2018-06-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IIFL 532636

0
IIFL Holdings Limited - Updates

2018-06-22 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IIFL 532636

0
IIFL Wealth to raise ₹745.71 cr

2018-06-20 thehindubusinessline
Our Bureau IIFL Wealth Management (IIFL-WM), an arm of IIFL Holdings, on Wednesday approved the issue of 5.1 per cent equity to marquee financial investors for ₹745.71 crore. The proposed transaction will provide IIFL-WM with additional capital for its business operations and general corporate purposes as well as for growth and expansion of business.
IIFL 532636

0
IIFL Holdings Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-20 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
IIFL 532636

Related Articles

CATB: Catabasis Pharmaceuticals Analysis and Research Report

2018-07-13 - Asif

Overview Catabasis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics based on its proprietary Safely Metabolized And Rationally Targeted linker, or SMART LinkerSM, drug discovery platform. The company's SMART Linker drug discovery platform enables it to engineer product candidates that can simultaneously modulate multiple targets in a disease. The company's proprietary product candidates impact pathways that are central to diseases where efficacy may be optimized by a multiple target approach. Catabasis Pharmaceuticals has applied its SMART Linker drug discovery platform to build an internal pipeline of product candidates for rare diseases, its primary focus, and plan to pursue partnerships to develop additional product candidates. The company's lead product candidate is edasalonexent, formerly known as CAT-1004, which the company believe has the potential to be a disease-modifying...

WMT: Walmart Analysis and Research Report

2018-07-09 - Asif

Overview Walmart Inc. helps people around the world save money and live better – anytime and anywhere – in retail stores and through eCommerce. Through innovation, Walmart is striving to create a customer-centric experience that seamlessly integrates its eCommerce and retail stores in an omni-channel offering that saves time for its customers. Each week, the company serve nearly 270 million customers who visit its more than 11,700 stores and numerous eCommerce websites under 65 banners in 28 countries. The company's strategy is to lead on price, invest to differentiate on access, be competitive on assortment and deliver a great experience. Leading on price is designed to earn the trust of its customers every day by providing a broad assortment of quality merchandise and services at everyday low prices ("EDLP"). EDLP is its pricing philosophy under which the company price items at a low price every day so its customers trust that its prices will not change under frequent prom...

NVRO: Nevro Corp Analysis and Research Report

2018-07-06 - Asif

Overview Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. The company's proprietary paresthesia-free HF10TM therapy, delivered by its Senza system, was demonstrated in its SENZA-RCT study to be superior to traditional SCS therapy with it being nearly twice as successful in treating back pain and 1.5 times as successful in treating leg pain when compared to traditional SCS therapy. Comparatively, traditional SCS therapy has limited efficacy in treating back pain and is used primarily for treating leg pain, limiting its market adoption. The company's SENZA-RCT study, along with its European studies, represents what the company believe is the most robust body of clinical evidence for any SCS therapy. The compa...